33 results about "Plasmacytoid dendritic cell" patented technology

To provide an oral composition for effectively activating plasmacytoid dendritic cells (pDCs).SOLUTION: An oral composition for activating plasmacytoid dendritic cells (pDCs), comprising Lacticaseibacillus rhamnosus CRL1505, wherein the composition is preferably intended for immune activation. The oral composition for activating pDCs is considered to: regulate both innate immunity and acquired immunity; act on an overall immune function, maintain a normal immune function, and maintain good physical conditions. The present invention also provides an oral composition for immune activation characterised in that it comprises Lacticaseibacillus rhamnosus CRL1505, wherein the immune activation is intended for symptoms such as nasal congestion.SELECTED DRAWING: Figure 1

Antibodies and antibody fragments that bind to BDCA2 are disclosed. Also disclosed are methods of using the antibodies and antibody fragments to induce death of a plasmacytoid dendritic cell, inhibit production or secretion of inflammatory cytokines and chemokines, and treat or prevent immunological disorders such as inflammatory and autoimmune conditions.

Disclosed is a method for evaluating the immunostimulatory capacity of a target substance, the method including a contacting step in which a human plasmacytoid dendritic cell line is cultured in the presence of the target substance, wherein the human plasmacytoid dendritic cell line is the CAL-1 cell line (accession number FERM BP-10914), and the CAL-1 cells are in a starvation state during at least part of the contacting step.

To provide an immunostimulating composition.SOLUTION: An immunostimulating composition comprises, as an active ingredient, a bacterium that is phagocytosed by plasmacytoid dendritic cells (pDC) at or above a predetermined level.SELECTED DRAWING: None

The invention discloses an antibody composition for detecting mother cell plasma cell-like dendritic cells. The antibody composition comprises a first group of antibodies, a second group of antibodies, a third group of antibodies and a fourth group of antibodies, the first group of antibodies comprises a CD36 antibody, a CD4 antibody, a CD14 antibody, a CD56 antibody, a CD5 antibody, a CD3 antibody, a CD8 antibody, a CD2 antibody, a CD7 antibody and a CD45 antibody; the second group of antibodies comprises an HLA-DR (Human Leukocyte Antigen-DR) antibody, a CD33 antibody, a CD34 antibody, a CD56 antibody, a CD117 antibody, a CD123 antibody, a CD19 antibody, a CD38 antibody and a CD45 antibody; the third group of antibodies comprises a CD303 antibody, a CD304 antibody, a CD41 antibody, a CD56 antibody, a CD13 antibody, a CD85j antibody, a CD64 antibody, a CD15 antibody and a CD45 antibody; and the fourth group of antibodies comprises TdT, MPO, CD56, cCD3, CD10, cCD22 and CD45 antibodies. The antibody composition can be used for accurately detecting tumor abnormal BPDCN cells.

Disclosed is an immunostimulatory composition containing, as an active ingredient, bacteria which bond to BDCA2 and / or bacteria which are phagocytosed by plasmacytoid dendritic cells (pDCs) to at least a prescribed degree.

The present invention relates to a biomarker for diagnosing pediatric atopic dermatitis and use thereof. As result of comparing immune phenotypes of a healthy control group with those of pediatric atopic dermatitis patients, it has been identified that Th1, Th2, Th17 and Th22 cells or expression of STAT1, CD6 and ALCAM genes are increased or decreased. In addition, in the present invention, it has been identified that the frequencies of monocytes, plasmacytoid dendritic cells, CD4 central memory T cells, and CD4 effector memory T cells are related to the severity of pediatric atopic dermatitis. Therefore, the present invention can ensure an efficient treatment strategy for pediatric atopic dermatitis by accurately diagnosing pediatric atopic dermatitis and the severity thereof.

Disclosed herein are anti-BDCA2 antibodies and antigen binding fragments, polynucleotides encoding the antibodies and antigen binding fragments, and pharmaceutical compositions comprising the antibodies and antigen binding fragments. Also disclosed is the use of the anti-BDCA2 antibodies and antigen binding fragments described herein in the treatment of plasma cell-like dendritic cell (pDC) or type I interferon (type I IFN) related immunological disorders.

The present invention addresses the problem of providing a composition, for activating plasmacytoid dendritic cells, which has a high level of safety and can be taken by a large number of people more easily. A composition for activating plasmacytoid dendritic cells according to the present invention contains one or more lactic acid bacteria selected from Lactobacillus lactic acid bacteria (excluding Lactobacillus helveticus), Lacticaseibacillus lactic acid bacteria, and lactic acid bacteria belonging to Streptococcus thermophilus. It is to be noted that the above-mentioned composition for activating plasmacytoid dendritic cells preferably contains Lactobacillus lactic acid bacteria (excluding Lactobacillus helveticus), Lacticaseibacillus lactic acid bacteria, and lactic acid bacteria belonging to Streptococcus thermophilus.

The present invention provides a composition for use in applications such as activating plasmacytoid dendritic cells (pDCs), the composition containing Lactobacillus sakei, MG-LAB279 strain (accession number: NITE BP-03645), and / or a bacterial cell component thereof as an active ingredient.

To provide an anti-blood dendritic cell antigen 2 antibody and its use. [Solution] Antibodies and antibody fragments that bind to BDCA2 are disclosed. Also disclosed are methods for using the above antibodies and antibody fragments to induce plasmacytoid dendritic cell death, inhibit the production or secretion of inflammatory cytokines and chemokines, and treat or prevent immune disorders such as inflammatory and autoimmune conditions. (i) an isolated antibody or its antigen-binding fragment that selectively binds to the extracellular domain of human BDCA2, and (ii) competes with BIIB059 for binding to the extracellular domain of human BDCA2.

Disclosed herein are compositions comprising a hydrogel scaffold, methods of generating a hydrogel scaffold, and systems for and methods of using the hydrogel scaffold to produce biologically active molecules.

The present invention discloses an anti-BDCA2 antibody and its antigen-binding fragment, a polynucleotide encoding the antibody and its antigen-binding fragment, and a pharmaceutical composition comprising the antibody and its antigen-binding fragment. Furthermore, the use of the anti-BDCA2 antibody and its antigen-binding fragment described in the present invention in the treatment of plasmacytoid dendritic cell (pDC) or type I interferon (type I IFN)-associated immune diseases is also disclosed.

To provide a composition for activating plasmacytoid dentritic cells, which does not require expensive culture equipment for its active ingredient (Tetragenococcus lactic acid bacteria), hardly requires labor and cost in production, is a safe food material, and further activates plasmacytoid dentritic cells.SOLUTION: The composition for activating the plasmacytoid dentritic cells contains at least one kind selected from Tetragenococcus lactic acid bacteria activating the plasmacytoid dentritic cells and cultures of the lactic acid bacteria.SELECTED DRAWING: None

To provide a composition for immunostimulation.SOLUTION: A composition for immunostimulation comprising, as an active ingredient, a bacterium phagocytosed by plasmacytoid dentritic cells (pDCs) to a predetermined degree or more and / or a bacterium binding to BDCA2.SELECTED DRAWING: None

The present application relates to the technical field of medical immunology, and particularly relates to application of plasma cell-like dendritic cells as a marker in a prognosis product for children sepsis. The present application detects the pDC level in the peripheral blood of a patient based on flow cytometry, and evaluates the prognosis of the patient based on the expression level. The pDC expression level is significantly positively correlated with the children sepsis score (Phoenix and pSOFA score), and is positively correlated with the mortality rate of children with sepsis. When the expression of pDC is higher than 0.96%, it indicates that the patient has a higher risk of death. The method of the present application can provide accurate prognosis evaluation in the early screening of children sepsis, has high specificity and sensitivity, helps doctors to timely adjust the treatment scheme, optimizes personalized treatment, and has good practical application value.

Disclosed herein are compositions comprising a hydrogel scaffold, methods of generating a hydrogel scaffold, and systems for and methods of using the hydrogel scaffold to produce biologically active molecules.

The application uses a BDCA-2 extracellular domain (ECD) antigen to immunize a fully humanized mouse, and through a hybridoma technology, a positive clone is screened, and through gene sequencing and recombinant expression purification, a specific monoclonal antibody targeting human plasmacytoid dendritic cells is obtained. The antibody has high binding capacity for human BDCA-2, and can be used for the development of therapeutic or prophylactic drugs or diagnostic reagents for inflammatory diseases or autoimmune diseases.

The present application relates to a method of treating a respiratory viral infection in a patient in need thereof comprising administering to the patient a therapeutically effective amount of an agent that depletes plasmacytoid dendritic cells. Another object of the present application relates to a kit of part comprising said agent and at least one further therapeutic agent as a combined preparation for simultaneous, separate or sequential use in the treatment of a respiratory viral infection in a subject in need thereof.

Provided herein are IL-10 variant sequences. In some embodiments, the IL-10 variants are immunosilent, and / or are capable of suppressing monocyte, macrophage, or pDC activity. Also disclosed herein are vaccines comprising the IL-10 variants, and methods of treatment for diseases and disorders that correspond with activating adaptive immunity.

This invention provides an IFN inducer comprising, as an active ingredient, lactic acid bacteria and capable of inducing IFN production, an immunopotentiating agent or prophylactic agent against virus infection comprising such inducer, and a food or drink product comprising such IFN inducer and having IFN-inducing activity, immunopotentiating activity, or prophylactic activity against virus infection. The agent for inducing IFN production comprises, as active ingredients, lactic acid bacteria that can activate plasmacytoid dendritic cells (pDCs) and promote IFN production, such as Lactococcus garvieae NBRC100934, Lactococcus lactis subsp. cremoris JCM16167, Lactococcus lactis subsp. cremoris NBRC100676, Lactococcus lactis subsp. hordniae JCM1180, Lactococcus lactis subsp. hordniae JCM11040, Lactococcus lactis subsp. lactis NBRC12007, Lactococcus lactis subsp. lactis NRIC1150, Lactococcus lactis subsp. lactis JCM5805, Lactococcus lactis subsp. lactis JCM20101, Leuconostoc lactis NBRC12455, Leuconostoc lactis NRIC1540, Pediococcus damnosus JCM5886, or Streptococcus thermophilus TA-45.

The diagnostic markers that provide novel diagnostic criteria to blastic plasmacytoid dendritic cell neoplasm (BPDCN) has been searched, and the presence of immunoblastoid cytomorphology, 8q24 rearrangement, and MYC expression were established as novel markers for subtyping BPDCN. It has been further found that the inhibitors which directly or indirectly inhibit the expression, functions, or signaling pathways of MYC, such as BET bromodomain-selective inhibitors or aurora kinase inhibitors, are effective in MYC-positive BPDCN, and HDAC inhibitors or BCL2 family protein inhibitors are effective as therapeutic drugs for BPDCN.

The present invention addresses the problem of providing a bacterium belonging to Lactobacillus helveticus, which has an excellent IFN production-inducing effect. The present invention relates to a bacterium classified as Lactobacillus helveticus, which is capable of activating plasma-like dendritic cells (pDC) and / or myeloid dendritic cells (mDC) and inducing the production of type I IFN, and which induces the production of type I IFN at a level of 1.5 times or more as compared to that of Lactobacillus helveticus SBT2171 (accession number: Ferm BP-5445), and more particularly, to a bacterium classified as Lactobacillus helveticus, which is capable of activating plasma-like dendritic cells (pDC) and / or myeloid dendritic cells (mDC) and inducing the production of type I IFN at a level of 1.5 times or more than that of Lactobacillus helveticus SBT2171 (accession number: Ferm BP-5445).

To provide methods for treating cancer using combinations and adjunct therapies of therapeutic agents. [Solution] A pharmaceutical composition comprising (i) a mixture of 1) an effective amount of anti-PD-1 antibody and 2) one or more pharmaceutically acceptable carriers, excipients, or diluents, and (ii) a pharmaceutical composition comprising a mixture of 1) an effective amount of immunotherapeutic capable of activating human plasmacytoid dendritic cells, myeloid dendritic cells, or NK cells, or a combination thereof, and 2) one or more pharmaceutically acceptable carriers, excipients, or diluents, wherein the immunotherapeutic is 4-amino-2-(ethoxymethyl)-a,a-dimethyl-1H-imidazo[4,5-c]quinoline-1-ethanol (reximod).

The present disclosure relates to compositions, constructs and vectors for reprogramming cells into plasmacytoid dendritic cells or interferon type I-producing cells, methods and uses thereof. The present disclosure relates to the development of methods for making plasmacytoid dendritic cells or interferon type I-producing cells that promote antiviral and anti-tumoral immune responses from differentiated, multipotent or pluripotent stem cells by introducing and expressing isolated / synthetic transcription factors. More particularly, the disclosure provides methods for obtain plasmacytoid dendritic cells or interferon type I-producing cells by direct cellular reprogramming with the surprisingly use of combinations of specific transcription factors.

Compositions, methods, and kits are provided for diagnosing bacterial infections that distinguish tissue infected with dormant bacteria from uninfected tissue. In particular, the subject methods can be used to detect dormant bacteria, including bacteria in biofilms on joint replacement implants by measuring biomarkers in synovial fluid or blood or analyzing specific immune cell types, including regulatory T-cells, natural killer cells, monocytes, plasmacytoid dendritic cells, or myeloid dendritic cells within a periarticular tissue sample in contact with the effective joint space of an implant.

The invention provides a biomarker combination for in-vitro diagnosis of membranous nephropathy. The biomarker combination comprises non-classical mononuclear cells, CD4 + T cells, effector CD4 + T cells, 2-type helper T cells, double-negative T cells, central memory CD4 + T cells, plasma cell-like dendritic cells, antibody secreting cells, total T cells, unconverted memory B cells, classical mononuclear cells and natural killer cells. The invention also provides a construction method of the membranous nephropathy diagnosis model. The construction method comprises a step of screening the characteristic biomarkers and a step of constructing the diagnosis model and evaluating the performance. According to the method, the optimal marker combination is screened out from the high-dimensional flow cytometry data by applying a random forest recursive feature elimination algorithm, and a random forest diagnosis model is constructed. The invention shows excellent performance in distinguishing membranous nephropathy patients from healthy controls, and shows high accuracy in independent verification including a diagnosis difficulty subgroup of PLA2R antibody negative.

The present invention addresses the problem of providing a novel means for activating plasmacytoid dendritic cells (pDC). This pDC activator contains: bacterial cells of spore-forming bacteria; or a component, content, or a secretion thereof, or a culture composition thereof. The spore-forming bacterium is preferably a bacterium belonging to the genus Bacillus, the genus Weizmannia or the genus Heyndrickxia such as Heyndrickxia coagulans strain SANK 702558 or a derivative strain thereof.

The present disclosure relates to compositions, constructs and vectors for reprogramming cells into plasmacytoid dendritic cells or interferon type I-producing cells, methods and uses thereof. The present disclosure relates to the development of methods for making plasmacytoid dendritic cells or interferon type I-producing cells that promote antiviral and anti-tumoral immune responses from differentiated, multipotent or pluripotent stem cells by introducing and expressing isolated / synthetic transcription factors. More particularly, the disclosure provides methods for obtain plasmacytoid dendritic cells or interferon type I-producing cells by direct cellular reprogramming with the surprisingly use of combinations of specific transcription factors.

The present invention relates, in part, to agents, chimeric proteins and chimeric protein complexes that bind a plasmacytoid dendritic cell (pDC), e.g. Clec4C and their use as diagnostic and therapeutic agents. The present Invention further relates to pharmaceutical compositions comprising the pDC, e.g. Clec4C, binding agents, chimeric proteins, or chimeric protein complexes and their use in the treatment of various diseases, including autoimmune diseases.